Search

Your search keyword '"Stuckey, Jeanne A."' showing total 522 results
Start Over Author "Stuckey, Jeanne A."
522 results on '"Stuckey, Jeanne A."'

1. Human SIRT5 variants with reduced stability and activity do not cause neuropathology in mice

Author

Yuan, Taolin, Kumar, Surinder, Skinner, Mary E., Victor-Joseph, Ryan, Abuaita, Majd, Keijer, Jaap, Zhang, Jessica, Kunkel, Thaddeus J., Liu, Yanghan, Petrunak, Elyse M., Saunders, Thomas L., Lieberman, Andrew P., Stuckey, Jeanne A., Neamati, Nouri, Al-Murshedi, Fathiya, Alfadhel, Majid, Spelbrink, Johannes N., Rodenburg, Richard, de Boer, Vincent C.J., and Lombard, David B.

Published
2024
Full Text
View/download PDF

6. D3R grand challenge 2015: Evaluation of protein–ligand pose and affinity predictions

Author

Gathiaka, Symon, Liu, Shuai, Chiu, Michael, Yang, Huanwang, Stuckey, Jeanne A, Kang, You Na, Delproposto, Jim, Kubish, Ginger, Dunbar, James B, Carlson, Heather A, Burley, Stephen K, Walters, W Patrick, Amaro, Rommie E, Feher, Victoria A, and Gilson, Michael K

Subjects
Medicinal and Biomolecular Chemistry, Chemical Sciences, Generic health relevance, Binding Sites, Crystallography, X-Ray, Drug Design, HSP90 Heat-Shock Proteins, Ligands, Molecular Docking Simulation, Protein Binding, Protein Conformation, Quantitative Structure-Activity Relationship, D3R, Docking, Scoring, Free energy, Ligand, Protein, Theoretical and Computational Chemistry, Medicinal & Biomolecular Chemistry, Medicinal and biomolecular chemistry, Theoretical and computational chemistry
Abstract

The Drug Design Data Resource (D3R) ran Grand Challenge 2015 between September 2015 and February 2016. Two targets served as the framework to test community docking and scoring methods: (1) HSP90, donated by AbbVie and the Community Structure Activity Resource (CSAR), and (2) MAP4K4, donated by Genentech. The challenges for both target datasets were conducted in two stages, with the first stage testing pose predictions and the capacity to rank compounds by affinity with minimal structural data; and the second stage testing methods for ranking compounds with knowledge of at least a subset of the ligand-protein poses. An additional sub-challenge provided small groups of chemically similar HSP90 compounds amenable to alchemical calculations of relative binding free energy. Unlike previous blinded Challenges, we did not provide cognate receptors or receptors prepared with hydrogens and likewise did not require a specified crystal structure to be used for pose or affinity prediction in Stage 1. Given the freedom to select from over 200 crystal structures of HSP90 in the PDB, participants employed workflows that tested not only core docking and scoring technologies, but also methods for addressing water-mediated ligand-protein interactions, binding pocket flexibility, and the optimal selection of protein structures for use in docking calculations. Nearly 40 participating groups submitted over 350 prediction sets for Grand Challenge 2015. This overview describes the datasets and the organization of the challenge components, summarizes the results across all submitted predictions, and considers broad conclusions that may be drawn from this collaborative community endeavor.

Published
2016

7. KRAS Engages AGO2 to Enhance Cellular Transformation

Author

Shankar, Sunita, Pitchiaya, Sethuramasundaram, Malik, Rohit, Kothari, Vishal, Hosono, Yasuyuki, Yocum, Anastasia K, Gundlapalli, Harika, White, Yasmine, Firestone, Ari, Cao, Xuhong, Dhanasekaran, Saravana M, Stuckey, Jeanne A, Bollag, Gideon, Shannon, Kevin, Walter, Nils G, Kumar-Sinha, Chandan, and Chinnaiyan, Arul M

Subjects
Biochemistry and Cell Biology, Biological Sciences, Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Argonaute Proteins, Base Sequence, Carboxypeptidases, Cell Transformation, Neoplastic, Endoplasmic Reticulum, Gene Expression Regulation, Neoplastic, Gene Silencing, Humans, Mice, MicroRNAs, Molecular Sequence Data, Mutation, NIH 3T3 Cells, Phosphatidylinositol 3-Kinases, Protein Binding, Proto-Oncogene Proteins p21(ras), RNA, Small Interfering, Transgenes, Argonaute 2, EIF2C2, KRAS, RNA silencing, cancer, Medical Physiology, Biological sciences
Abstract

Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant KRAS-dependent cells and AGO2 overexpression enhances KRAS(G12V)-mediated transformation. Using AGO2-/- cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.

Published
2016

12. Changing the Apoptosis Pathway through Evolutionary Protein Design

Author

Shultis, David, Mitra, Pralay, Huang, Xiaoqiang, Johnson, Jarrett, Khattak, Naureen Aslam, Gray, Felicia, Piper, Clint, Czajka, Jeff, Hansen, Logan, Wan, Bingbing, Chinnaswamy, Krishnapriya, Liu, Liu, Wang, Mi, Pan, Jingxi, Stuckey, Jeanne, Cierpicki, Tomasz, Borchers, Christoph H., Wang, Shaomeng, Lei, Ming, and Zhang, Yang

Published
2019
Full Text
View/download PDF

13. SIRT5 variants from patients with mitochondrial disease are associated with reduced SIRT5 stability and activity, but not with neuropathology

Author

Yuan, Taolin, primary, Kumar, Surinder, additional, Skinner, Mary E, additional, Victor-Joseph, Ryan, additional, Abuaita, Majd, additional, Keijer, Jaap, additional, Zhang, Jessica, additional, Kunkel, Thaddeus, additional, Liu, Yanghan, additional, Petrunak, Elyse, additional, Saunders, Thomas, additional, Lieberman, Andrew P., additional, Stuckey, Jeanne A., additional, Neamati, Nouri, additional, AlMurshedi, Fathiya, additional, Alfadhel, Majid, additional, Spelbrink, Johannes N, additional, Rodenburg, Richard, additional, de Boer, Vincent C.J., additional, and Lombard, David B, additional

Published
2023
Full Text
View/download PDF

16. CSAR data set release 2012: ligands, affinities, complexes, and docking decoys.

Author

Dunbar, James, Smith, Richard, Damm-Ganamet, Kelly, Ahmed, Aqeel, Esposito, Emilio, Delproposto, James, Chinnaswamy, Krishnapriya, Kang, You-Na, Kubish, Ginger, Stuckey, Jeanne, Carlson, Heather, and Gestwicki, Jason

Subjects
Databases, Pharmaceutical, Drug Design, Internet, Ligands, Molecular Docking Simulation, Protein Binding, Protein Conformation, Structure-Activity Relationship
Abstract

A major goal in drug design is the improvement of computational methods for docking and scoring. The Community Structure Activity Resource (CSAR) has collected several data sets from industry and added in-house data sets that may be used for this purpose ( www.csardock.org). CSAR has currently obtained data from Abbott, GlaxoSmithKline, and Vertex and is working on obtaining data from several others. Combined with our in-house projects, we are providing a data set consisting of 6 protein targets, 647 compounds with biological affinities, and 82 crystal structures. Multiple congeneric series are available for several targets with a few representative crystal structures of each of the series. These series generally contain a few inactive compounds, usually not available in the literature, to provide an upper bound to the affinity range. The affinity ranges are typically 3-4 orders of magnitude per series. For our in-house projects, we have had compounds synthesized for biological testing. Affinities were measured by Thermofluor, Octet RED, and isothermal titration calorimetry for the most soluble. This allows the direct comparison of the biological affinities for those compounds, providing a measure of the variance in the experimental affinity. It appears that there can be considerable variance in the absolute value of the affinity, making the prediction of the absolute value ill-defined. However, the relative rankings within the methods are much better, and this fits with the observation that predicting relative ranking is a more tractable problem computationally. For those in-house compounds, we also have measured the following physical properties: logD, logP, thermodynamic solubility, and pK(a). This data set also provides a substantial decoy set for each target consisting of diverse conformations covering the entire active site for all of the 58 CSAR-quality crystal structures. The CSAR data sets (CSAR-NRC HiQ and the 2012 release) provide substantial, publically available, curated data sets for use in parametrizing and validating docking and scoring methods.

Published
2013

17. Ordering a Dynamic Protein Via a Small-Molecule Stabilizer

Author

Wang, Ningkun, Majmudar, Chinmay Y, Pomerantz, William C, Gagnon, Jessica K, Sadowsky, Jack D, Meagher, Jennifer L, Johnson, Taylor K, Stuckey, Jeanne A, Brooks, Charles L, Wells, James A, and Mapp, Anna K

Subjects
Macromolecular and Materials Chemistry, Chemical Sciences, Underpinning research, 1.1 Normal biological development and functioning, Generic health relevance, Models, Molecular, Molecular Dynamics Simulation, Molecular Structure, Proteins, Small Molecule Libraries, Surface Properties, General Chemistry, Chemical sciences, Engineering
Abstract

Like many coactivators, the GACKIX domain of the master coactivator CBP/p300 recognizes transcriptional activators of diverse sequence composition via dynamic binding surfaces. The conformational dynamics of GACKIX that underlie its function also render it especially challenging for structural characterization. We have found that the ligand discovery strategy of Tethering is an effective method for identifying small-molecule fragments that stabilize the GACKIX domain, enabling for the first time the crystallographic characterization of this important motif. The 2.0 Å resolution structure of GACKIX complexed to a small molecule was further analyzed by molecular dynamics simulations, which revealed the importance of specific side-chain motions that remodel the activator binding site in order to accommodate binding partners of distinct sequence and size. More broadly, these results suggest that Tethering can be a powerful strategy for identifying small-molecule stabilizers of conformationally malleable proteins, thus facilitating their structural characterization and accelerating the discovery of small-molecule modulators.

Published
2013

18. Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors

Author

Yuan, Xinrui, primary, Jiang, Hua, additional, Fu, Denggang, additional, Rech, Jason C., additional, Robida, Aaron, additional, Rajanayake, Krishani, additional, Yuan, Hebao, additional, He, Miao, additional, Wen, Bo, additional, Sun, Duxin, additional, Liu, Chen, additional, Chinnaswamy, Krishnapriya, additional, Stuckey, Jeanne A., additional, Paczesny, Sophie, additional, and Yang, Chao-Yie, additional

Published
2023
Full Text
View/download PDF

22. Data from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Author

Abulwerdi, Fardokht, primary, Liao, Chenzhong, primary, Liu, Meilan, primary, Azmi, Asfar S., primary, Aboukameel, Amro, primary, Mady, Ahmed S.A., primary, Gulappa, Thippeswamy, primary, Cierpicki, Tomasz, primary, Owens, Scott, primary, Zhang, Tao, primary, Sun, Duxin, primary, Stuckey, Jeanne A., primary, Mohammad, Ramzi M., primary, and Nikolovska-Coleska, Zaneta, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Methods and Supplementary Figures 1 through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo

Author

Abulwerdi, Fardokht, primary, Liao, Chenzhong, primary, Liu, Meilan, primary, Azmi, Asfar S., primary, Aboukameel, Amro, primary, Mady, Ahmed S.A., primary, Gulappa, Thippeswamy, primary, Cierpicki, Tomasz, primary, Owens, Scott, primary, Zhang, Tao, primary, Sun, Duxin, primary, Stuckey, Jeanne A., primary, Mohammad, Ramzi M., primary, and Nikolovska-Coleska, Zaneta, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

27. Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Author

Bai, Longchuan, primary, Zhou, Bing, primary, Yang, Chao-Yie, primary, Ji, Jiao, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Jiang, Hui, primary, Hu, Jiantao, primary, Xu, Fuming, primary, Zhao, Yujun, primary, Liu, Liu, primary, Fernandez-Salas, Ester, primary, Xu, Jing, primary, Dou, Yali, primary, Wen, Bo, primary, Sun, Duxin, primary, Meagher, Jennifer, primary, Stuckey, Jeanne, primary, Hayes, Daniel F., primary, Li, Shunqiang, primary, Ellis, Matthew J., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

28. Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Author

Bai, Longchuan, primary, Zhou, Bing, primary, Yang, Chao-Yie, primary, Ji, Jiao, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Jiang, Hui, primary, Hu, Jiantao, primary, Xu, Fuming, primary, Zhao, Yujun, primary, Liu, Liu, primary, Fernandez-Salas, Ester, primary, Xu, Jing, primary, Dou, Yali, primary, Wen, Bo, primary, Sun, Duxin, primary, Meagher, Jennifer, primary, Stuckey, Jeanne, primary, Hayes, Daniel F., primary, Li, Shunqiang, primary, Ellis, Matthew J., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

29. Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Author

Bai, Longchuan, primary, Zhou, Bing, primary, Yang, Chao-Yie, primary, Ji, Jiao, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Jiang, Hui, primary, Hu, Jiantao, primary, Xu, Fuming, primary, Zhao, Yujun, primary, Liu, Liu, primary, Fernandez-Salas, Ester, primary, Xu, Jing, primary, Dou, Yali, primary, Wen, Bo, primary, Sun, Duxin, primary, Meagher, Jennifer, primary, Stuckey, Jeanne, primary, Hayes, Daniel F., primary, Li, Shunqiang, primary, Ellis, Matthew J., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

30. Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Author

Bai, Longchuan, primary, Zhou, Bing, primary, Yang, Chao-Yie, primary, Ji, Jiao, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Jiang, Hui, primary, Hu, Jiantao, primary, Xu, Fuming, primary, Zhao, Yujun, primary, Liu, Liu, primary, Fernandez-Salas, Ester, primary, Xu, Jing, primary, Dou, Yali, primary, Wen, Bo, primary, Sun, Duxin, primary, Meagher, Jennifer, primary, Stuckey, Jeanne, primary, Hayes, Daniel F., primary, Li, Shunqiang, primary, Ellis, Matthew J., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

31. Data from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

Author

Lu, Jianfeng, primary, Bai, Longchuan, primary, Sun, Haiying, primary, Nikolovska-Coleska, Zaneta, primary, McEachern, Donna, primary, Qiu, Su, primary, Miller, Rebecca S., primary, Yi, Han, primary, Shangary, Sanjeev, primary, Sun, Yi, primary, Meagher, Jennifer L., primary, Stuckey, Jeanne A., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

Author

Lu, Jianfeng, primary, Bai, Longchuan, primary, Sun, Haiying, primary, Nikolovska-Coleska, Zaneta, primary, McEachern, Donna, primary, Qiu, Su, primary, Miller, Rebecca S., primary, Yi, Han, primary, Shangary, Sanjeev, primary, Sun, Yi, primary, Meagher, Jennifer L., primary, Stuckey, Jeanne A., primary, and Wang, Shaomeng, primary

Published
2023
Full Text
View/download PDF

33. Three Supplementary Tables and Supplementary Figures S1-S13 from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Author

Wang, Shaomeng, primary, Sun, Wei, primary, Zhao, Yujun, primary, McEachern, Donna, primary, Meaux, Isabelle, primary, Barrière, Cédric, primary, Stuckey, Jeanne A., primary, Meagher, Jennifer L., primary, Bai, Longchuan, primary, Liu, Liu, primary, Hoffman-Luca, Cassandra Gianna, primary, Lu, Jianfeng, primary, Shangary, Sanjeev, primary, Yu, Shanghai, primary, Bernard, Denzil, primary, Aguilar, Angelo, primary, Dos-Santos, Odette, primary, Besret, Laurent, primary, Guerif, Stéphane, primary, Pannier, Pascal, primary, Gorge-Bernat, Dimitri, primary, and Debussche, Laurent, primary

Published
2023
Full Text
View/download PDF

34. Data from SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Author

Wang, Shaomeng, primary, Sun, Wei, primary, Zhao, Yujun, primary, McEachern, Donna, primary, Meaux, Isabelle, primary, Barrière, Cédric, primary, Stuckey, Jeanne A., primary, Meagher, Jennifer L., primary, Bai, Longchuan, primary, Liu, Liu, primary, Hoffman-Luca, Cassandra Gianna, primary, Lu, Jianfeng, primary, Shangary, Sanjeev, primary, Yu, Shanghai, primary, Bernard, Denzil, primary, Aguilar, Angelo, primary, Dos-Santos, Odette, primary, Besret, Laurent, primary, Guerif, Stéphane, primary, Pannier, Pascal, primary, Gorge-Bernat, Dimitri, primary, and Debussche, Laurent, primary

Published
2023
Full Text
View/download PDF

37. Engineering a Therapeutic Lectin by Uncoupling Mitogenicity from Antiviral Activity

Author

Swanson, Michael D., Boudreaux, Daniel M., Salmon, Loïc, Chugh, Jeetender, Winter, Harry C., Meagher, Jennifer L., André, Sabine, Murphy, Paul V., Oscarson, Stefan, Roy, René, King, Steven, Kaplan, Mark H., Goldstein, Irwin J., Tarbet, E. Bart, Hurst, Brett L., Smee, Donald F., de la Fuente, Cynthia, Hoffmann, Hans-Heinrich, Xue, Yi, Rice, Charles M., Schols, Dominique, Garcia, J. Victor, Stuckey, Jeanne A., Gabius, Hans-Joachim, Al-Hashimi, Hashim M., and Markovitz, David M.

Published
2015
Full Text
View/download PDF

40. Novel Chemical Series of Anti-ST2 Small Molecules Suppress Allogeneic T Cells Proliferation While Increasing Treg Cells and Improve Gvhd and Survival In Vivo

Author

Yang, Chao-Yie, primary, Yuan, Xinrui, additional, Jiang, Hua, additional, Rech, Jason C., additional, Fu, Denggang, additional, Robida, Aaron, additional, Rajanayake, Krishani, additional, Yuan, Hebao, additional, Wen, Bo, additional, Sun, Duxin, additional, Chinnaswamy, Krishnapriya, additional, Stuckey, Jeanne A., additional, and Paczesny, Sophie, additional

Published
2022
Full Text
View/download PDF

43. Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, additional, Fang, Douglas D., additional, Manna, Alak, additional, Wang, Guangfeng, additional, Wang, Hengbang, additional, Zhu, Saijie, additional, Chen, Jianyong, additional, Min, Ping, additional, Yin, Yan, additional, Dutta, Navnita, additional, Halder, Nabanita, additional, Ciccio, Gina, additional, Copland, John A., additional, Miller, James, additional, Han, Bing, additional, Bai, Longchuan, additional, Liu, Liu, additional, Wang, Mi, additional, McEachern, Donna, additional, Przybranowski, Sally, additional, Yang, Chao-Yie, additional, Stuckey, Jeanne A., additional, Wu, Depei, additional, Li, Caixia, additional, Ryan, Jeremy, additional, Letai, Anthony, additional, Ailawadhi, Sikander, additional, Yang, Dajun, additional, Wang, Shaomeng, additional, Chanan-Khan, Asher, additional, and Zhai, Yifan, additional

Published
2022
Full Text
View/download PDF

50. Structure-Activity Relationship of 1-(Furan-2ymethyl)Pyrrolidinebbased Stimulation-2 (ST2) Inhibitors for Treating Graft Versus Host Disease

Author

Yuan, Xinrui, primary, Jiang, Hua, additional, Fu, Denggang, additional, Robida, Aaron, additional, Rajanayake, Krishani, additional, Yuan, Hebao, additional, Wen, Bo, additional, Sun, Duxin, additional, Watch, Brennan T., additional, Chinnaswamy, Krishnapriya, additional, Stuckey, Jeanne A., additional, Paczesny, Sophie, additional, Rech, Jason C., additional, and Yang, Chao-Yie, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results